This experience, and that of others with very rare genomic aberrations including MYCN amplification along with ALK amplification [61], MYCN promoter aberrations, or rare cases with newly diagnosed tumors with p53 mutations, may well describe an ultra-high-risk subgroup of LR-NB cases that deserve special attention. The gene discussed is MYCN; the disease is neuroblastoma.